| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 1,996 | 1,295 | 3,299 | 1,777 |
| Cost of revenue | 395 | 532 | 538 | 515 |
| Research and development | 15,657 | 16,584 | 13,028 | 11,449 |
| Revaluation of contingent consideration | NaN | 400 | 100 | 1,500 |
| General and administrative | 6,743 | 5,576 | 4,871 | 5,386 |
| Licensing | 1,393 | 937 | 1,911 | 1,335 |
| Total costs and expenses | 24,188 | 24,029 | 20,448 | 20,185 |
| Loss from operations | -22,192 | -22,734 | -17,149 | -18,408 |
| Interest income | 1,514 | 1,634 | 1,819 | 2,018 |
| Non-cash royalty income | 854 | 1,305 | 716 | 961 |
| Total other income | 2,368 | 2,939 | 2,535 | 2,979 |
| Net loss | -19,824 | -19,795 | -14,614 | -15,429 |
| Unrealized (loss) gain on marketable securities, net of tax of 0 | -588 | 13 | 115 | 48 |
| Total other comprehensive (loss) income | -588 | 13 | 115 | 48 |
| Comprehensive loss | -20,412 | -19,782 | -14,499 | -15,381 |
| Basic EPS | -0.15 | -0.161 | -0.12 | -0.13 |
| Diluted EPS | -0.15 | -0.161 | -0.12 | -0.13 |
| Basic Average Shares | 128,810,050 | 122,668,383 | 122,619,311 | 122,580,967 |
| Diluted Average Shares | 128,810,050 | 122,668,383 | 122,619,311 | 122,580,967 |
Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS)